BR112021022739A2 - Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma - Google Patents

Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma

Info

Publication number
BR112021022739A2
BR112021022739A2 BR112021022739A BR112021022739A BR112021022739A2 BR 112021022739 A2 BR112021022739 A2 BR 112021022739A2 BR 112021022739 A BR112021022739 A BR 112021022739A BR 112021022739 A BR112021022739 A BR 112021022739A BR 112021022739 A2 BR112021022739 A2 BR 112021022739A2
Authority
BR
Brazil
Prior art keywords
variant
fragment
composition
production method
treat cancer
Prior art date
Application number
BR112021022739A
Other languages
English (en)
Inventor
Jae Park Soon
Chung Hye-Shin
Joo Lee Seung
KIM Kyuwan
Song Hyung-Nam
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of BR112021022739A2 publication Critical patent/BR112021022739A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

VARIANTE DE PH20 OU FRAGMENTO, MÉTODO DE PRODUÇÃO E COMPOSIÇÃO PARA TRATAR CÂNCER COMPREENDENDO A VARIANTE OU FRAGMENTO DA MESMA. A presente invenção trata de variantes de PH20 ou fragmentos das mesmas com estabilidade térmica melhorada e atividade enzimática da hialuronidase humana, que é uma enzima que hidrolisa o ácido hialurônico e, mais particularmente, novas variantes de PH20 ou fragmentos das mesmas, incluindo uma ou mais substituições de resíduos de aminoácidos na variante com a sequência de aminoácidos de SEQ ID NO: 3, em que um ou mais resíduos de aminoácidos no N-terminal e/ou C-terminal são opcionalmente ainda deletados.
BR112021022739A 2020-01-23 2021-01-25 Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma BR112021022739A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200009046 2020-01-23
PCT/KR2021/000943 WO2021150079A1 (ko) 2020-01-23 2021-01-25 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
BR112021022739A2 true BR112021022739A2 (pt) 2022-08-09

Family

ID=76992900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022739A BR112021022739A2 (pt) 2020-01-23 2021-01-25 Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma

Country Status (12)

Country Link
US (1) US20230250408A1 (pt)
EP (1) EP3992285A4 (pt)
JP (1) JP2022552756A (pt)
KR (1) KR20220069045A (pt)
CN (1) CN113840921A (pt)
AU (2) AU2021211348B2 (pt)
BR (1) BR112021022739A2 (pt)
CA (1) CA3137324A1 (pt)
MX (1) MX2022008060A (pt)
TW (2) TW202140780A (pt)
WO (1) WO2021150079A1 (pt)
ZA (1) ZA202206370B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2023042096A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR20240000391A (ko) * 2022-06-22 2024-01-02 (주)알테오젠 N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
WO2024005502A1 (ko) * 2022-06-29 2024-01-04 주식회사 오디스젠 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588638A (en) * 2008-04-14 2012-09-28 Halozyme Inc Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides
MX2011006110A (es) * 2008-12-09 2011-06-24 Halozyme Inc Polipeptidos ph20 solubles extendidos y usos de los mismos.
US9447401B2 (en) * 2011-12-30 2016-09-20 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
KR20210023798A (ko) 2018-07-25 2021-03-04 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
JOP20210262A1 (ar) * 2019-03-25 2023-01-30 Alteogen Inc تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد

Also Published As

Publication number Publication date
EP3992285A1 (en) 2022-05-04
KR20220069045A (ko) 2022-05-26
US20230250408A1 (en) 2023-08-10
WO2021150079A1 (ko) 2021-07-29
EP3992285A4 (en) 2023-01-25
AU2024200091A1 (en) 2024-01-25
CA3137324A1 (en) 2021-07-29
CN113840921A (zh) 2021-12-24
JP2022552756A (ja) 2022-12-20
AU2021211348A1 (en) 2021-12-09
TW202140780A (zh) 2021-11-01
MX2022008060A (es) 2022-07-27
ZA202206370B (en) 2023-06-28
TW202302845A (zh) 2023-01-16
AU2021211348B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
BR112021022739A2 (pt) Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma
MX2020009824A (es) Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
Lee et al. Purification, molecular cloning, and sequencing of phospholipase C-beta 4.
Kock et al. Structure and function of recombinant cobra venom factor
BR112013013548B8 (pt) Proteína de fusão anticancerígena
Arrutia et al. Influence of heat pre-treatment on BSA tryptic hydrolysis and peptide release
Vivas-Ruiz et al. Biochemical and molecular characterization of the hyaluronidase from Bothrops atrox Peruvian snake venom
NZ603990A (en) Biotechnological production of chondroitin
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
Clement et al. Identification, cDNA cloning and heterologous expression of a hyaluronidase from the tarantula Brachypelma vagans venom
Messina et al. Identification and characterization of a bacterial hyaluronidase and its production in recombinant form
BR112021018461A2 (pt) Proteínas de fusão, bactérias recombinantes e fragmentos de exospório para saúde da planta
KR20210126019A (ko) 엔지니어링된 아릴 설페이트-의존 효소
BRPI0914244A2 (pt) Enzima com atividade contra clostridium
PE20230487A1 (es) Variantes de alfa-galactosidasa humana
EP2992892A1 (en) Fusion protein for use in the treatment of mitochondrial diseases
BR112022011332A2 (pt) Vetor de vírus adeno-associado recombinante, vírus adeno-associado recombinante, e, método para tratar um indivíduo com síndrome de hunter
BR112022009620A2 (pt) Fungo filamentoso mutante e método para a produção de proteína usando o mesmo
Poutou-Piñales et al. Human sulfatase transiently and functionally active expressed in E. coli K12
BR112021020926A2 (pt) Um novo tipo de composição de enzima
CA3091943A1 (en) Variants of porcine trypsin
AU2012292163A1 (en) Alteration of proteolytic cleavage of botulinum neurotoxins
Garg et al. Purification and characterization of iduronic acid-rich and glucuronic acid-rich proteoglycans implicated in human post-burn keloid scar
Rajput et al. Zebrafish acid ceramidase: Expression in Pichia pastoris GS115and biochemical characterization